17:00 , Aug 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy A biomanufacturing method could enable ex vivo production of human platelets to treat thrombocytopenia and other hematologic indications. In human induced pluripotent stem (iPS) cell-derived megakaryocyte cell lines cultured in shaking flasks,...
17:07 , Sep 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Osteoporosis Mouse studies suggest inhibiting senescent cells could help treat age-related bone loss. In aged, transgenic mice expressing the senescence marker human CDKN2A, a tool compound that depletes CDKN2A-positive cells decreased the number of senescent...
07:00 , Mar 30, 2015 |  BioCentury  |  Emerging Company Profile

Effusion dissolution

Lung Therapeutics Inc. is developing therapies that prevent or resolve fibrosis to treat Orphan lung diseases. Lead product LTI-01 is a formulation of a fibrinolytic enzyme in preclinical development to prevent and clear loculated pleural...
08:00 , Feb 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Plasminogen activator inhibitor 1 (SERPINE1; PAI1)

Infectious disease INDICATION: Influenza virus Cell culture and mouse studies suggest SERPINE1 or SERPINE1 agonists could help treat influenza A viral infection. A high throughput microscopy screen in human lung cells engineered to express interferon (IFN)-stimulated genes...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

THR-18: Additional Phase IIa data

A double-blind, placebo-controlled, Ukrainian Phase IIa trial in 30 patients with acute ischemic stroke showed that THR-18 in combination with tissue plasminogen activator (tPA) met the primary safety endpoint. Specifically, no patients receiving THR-18...
07:00 , Jul 24, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Cancer; thrombosis Plasminogen activator inhibitor 1 (SERPINE1; PAI1) In vitro and mouse studies suggest enhancing the interaction...
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Other Plasminogen activator inhibitor 1 (SERPINE1; PAI1) Mouse studies suggest inhibiting PAI1 could prevent age-related tissue dysfunction....
07:00 , Jun 5, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Actin a2 smooth aorta muscle (ACTA2; a-SMA); smoothened (SMO); sonic hedgehog homolog (SHH) Studies in...
08:00 , Nov 21, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Computational models

This week in techniques Approach Summary Licensing status Publication and contact information Computational models Analysis of adverse events database to identify mechanisms underlying side effects In silico...
08:00 , Nov 14, 2013 |  BC Innovations  |  Cover Story

Trends with benefits

The FDA set up its adverse event database decades ago to capture the side effects of marketed drugs, but a group from the Icahn School of Medicine at Mount Sinai has now exploited the millions...